Bruce Power is doubling its capacity to produce its cancer-fighting medical isotopes.
In partnership with Saugeen Ojibway Nation, Isogen, and ITM Isotope Technologies Munich SE, the company unveiled the installation of the second production line on Monday, which will increase the production of lutetium-177.
The isotope is used in targeted therapy for a variety of cancers, including prostate as well as neuroendocrine tumours.
President and CEO Mike Rencheck says Bruce Power is proud of its long legacy as a key producer of medical isotopes.
“Together with out partners, we are continuing to expand our capabilities to supply the isotopes needed to meet demand and advance research in cancer treatments and procedures to help save lives,” says Rencheck.
Both Chippewas of Nawash Unceded First Nation Chief Greg Nadjiwon and Chippewas of Saugeen First Nation Chief Conrad Ritchie were in attendance for the unveiling.
“We are proud of our inclusion in the growth of the field of nuclear medicine and the benefits it will deliver to so many people,” says Nadjiwon.
Ritchie adds, “we are proud to be a part of the global fight against cancer through this innovative project as demand for innovative treatments for cancer is increasing on a daily basis.”
The second production line will be entering commercial service later this year.
